Ong Shao Jin, Sharkey Lisa M, Low Kai En, Cheow Heok K, Butler Andrew J, Buscombe John R
Addenbrookes Hospital, Cambridge Universities Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK.
J Imaging. 2023 Jun 7;9(6):114. doi: 10.3390/jimaging9060114.
Multivisceral transplant (MVTx) refers to a composite graft from a cadaveric donor, which often includes the liver, the pancreaticoduodenal complex, and small intestine transplanted en bloc. It remains rare and is performed in specialist centres. Post-transplant complications are reported at a higher rate in multivisceral transplants because of the high levels of immunosuppression used to prevent rejection of the highly immunogenic intestine. In this study, we analyzed the clinical utility of 28 F-FDG PET/CT scans in 20 multivisceral transplant recipients in whom previous non-functional imaging was deemed clinically inconclusive. The results were compared with histopathological and clinical follow-up data. In our study, the accuracy of F-FDG PET/CT was determined as 66.7%, where a final diagnosis was confirmed clinically or via pathology. Of the 28 scans, 24 scans (85.7%) directly affected patient management, of which 9 were related to starting of new treatments and 6 resulted in an ongoing treatment or planned surgery being stopped. This study demonstrates that F-FDG PET/CT is a promising technique in identifying life-threatening pathologies in this complex group of patients. It would appear that F-FDG PET/CT has a good level of accuracy, including for those MVTx patients suffering from infection, post-transplant lymphoproliferative disease, and malignancy.
多脏器移植(MVTx)是指来自尸体供体的复合移植物,通常包括整块移植的肝脏、胰十二指肠复合体和小肠。这种移植仍然很少见,且在专科中心进行。由于用于预防高免疫原性肠道排斥反应的免疫抑制水平较高,多脏器移植术后并发症的报告发生率更高。在本研究中,我们分析了28例F-FDG PET/CT扫描在20例多脏器移植受者中的临床应用价值,这些受者之前的非功能性成像在临床上被认为无定论。将结果与组织病理学和临床随访数据进行比较。在我们的研究中,F-FDG PET/CT的准确性被确定为66.7%,最终诊断通过临床或病理学得到证实。在28次扫描中,24次扫描(85.7%)直接影响了患者的治疗管理,其中9次与开始新治疗有关,6次导致正在进行的治疗或计划中的手术停止。这项研究表明,F-FDG PET/CT在识别这类复杂患者群体中的危及生命的病变方面是一种有前景的技术。看来F-FDG PET/CT具有较高的准确性,包括对于那些患有感染、移植后淋巴细胞增生性疾病和恶性肿瘤的多脏器移植患者。